Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.55 |
| ▸ | CCNC | P24863 | 3/20 | 0.51 |
| ▸ | CDK8 | P49336 | 3/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.47 |
| ▸ | CLK1 | P49759 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908155 | 0.88 | USP30 (0.54) | USP30CCNCCDK8PIK3CGPIM1 | |
| SCHEMBL21033464 | 0.83 | KDM4E (0.55) | USP30PIK3CGEGLN1CLK1 | |
| SCHEMBL21033159 | 0.83 | EGLN1 (0.47) | USP30PIK3CGEGLN1PTGS1PTGS2 | |
| SCHEMBL21001602 | 0.80 | EGLN1 (0.45) | USP30EGLN1PTGS1PTGS2 | |
| SCHEMBL21033340 | 0.80 | CHEK1 (0.47) | USP30CCNCCDK8PIM1PIM2 | |
| SCHEMBL21033163 | 0.80 | EGLN1 (0.46) | EGLN1PTGS1PTGS2 | |
| SCHEMBL3660590 | 0.79 | EGLN1 (0.66) | EGLN1PTGS1PTGS2 | |
| SCHEMBL30977270 | 0.79 | EGLN1 (0.66) | EGLN1PTGS1PTGS2 | |
| SCHEMBL21033582 | 0.79 | EGLN1 (0.48) | EGLN1PTGS1PTGS2 | |
| SCHEMBL21033716 | 0.79 | CCNC (0.46) | USP30CCNCCDK8PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | JUBILANT EPISCRIBE LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC | 2021-12-02 | — | — | US | disclosed |
| WO-2019102494-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459338-B2 | Heterocyclic compounds as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | USP30 1944/4885CCNC 1286/4885CDK8 273/4885 |
| US-20210371431-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | USP30 1944/4885CCNC 1286/4885CDK8 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.